Back to (new) normality-A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2.
COVID-19
Cancer radiotherapy
Lombardy
Northern Italy
Survey
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
04 Nov 2020
04 Nov 2020
Historique:
received:
27
08
2020
accepted:
23
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Italy experienced one of the world's severest COVID-19 outbreak, with Lombardy being the most afflicted region. However, the imposed safety measures allowed to flatten the epidemic curve and hence to ease the restrictions and inaugurate, on the 4th of May 2020, the Italian phase (P) 2 of the pandemic. The present survey study, endorsed by CODRAL and AIRO-L, aimed to assess how radiotherapy (RT) departments in Lombardy have dealt with the recovery. A questionnaire dealing with the management of pandemic was developed online and sent to all CODRAL Directors on the 10th of June 2020. Answers were collected in full anonymity one week after. All the 33 contacted RT facilities (100%) responded to the survey. Despite the scale of the pandemic, during P1 14 (42.4%) centres managed to safely continue the activity (≤ 10% reduction). During P2, 10 (30.3%) centres fully recovered and 14 (42.4%) reported an increase. Nonetheless, 6 (18.2%) declared no changes and, interestingly, 3 (9.1%) reduced activities. Overall, 21 centres (63.6%) reported suspected or positive cases within healthcare workforce since the beginning of the pandemic. Staff units were quarantined in 19 (57.6%) and 6 (18.2%) centres throughout P1 and P2, respectively. In the two phases, about two thirds centres registered positive or suspected cases amongst patients. The study revealed a particular attention to anti-contagion measures and a return to normal or even higher clinical workload in most RT centres in Lombardy, necessary to carry out current and previously deferred treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Italy experienced one of the world's severest COVID-19 outbreak, with Lombardy being the most afflicted region. However, the imposed safety measures allowed to flatten the epidemic curve and hence to ease the restrictions and inaugurate, on the 4th of May 2020, the Italian phase (P) 2 of the pandemic. The present survey study, endorsed by CODRAL and AIRO-L, aimed to assess how radiotherapy (RT) departments in Lombardy have dealt with the recovery.
MATERIALS AND METHODS
METHODS
A questionnaire dealing with the management of pandemic was developed online and sent to all CODRAL Directors on the 10th of June 2020. Answers were collected in full anonymity one week after.
RESULTS
RESULTS
All the 33 contacted RT facilities (100%) responded to the survey. Despite the scale of the pandemic, during P1 14 (42.4%) centres managed to safely continue the activity (≤ 10% reduction). During P2, 10 (30.3%) centres fully recovered and 14 (42.4%) reported an increase. Nonetheless, 6 (18.2%) declared no changes and, interestingly, 3 (9.1%) reduced activities. Overall, 21 centres (63.6%) reported suspected or positive cases within healthcare workforce since the beginning of the pandemic. Staff units were quarantined in 19 (57.6%) and 6 (18.2%) centres throughout P1 and P2, respectively. In the two phases, about two thirds centres registered positive or suspected cases amongst patients.
CONCLUSION
CONCLUSIONS
The study revealed a particular attention to anti-contagion measures and a return to normal or even higher clinical workload in most RT centres in Lombardy, necessary to carry out current and previously deferred treatments.
Identifiants
pubmed: 33150476
doi: 10.1007/s12032-020-01434-1
pii: 10.1007/s12032-020-01434-1
pmc: PMC7641253
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Clin Transl Radiat Oncol. 2020 Jun 30;24:88-91
pubmed: 32665983
Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281
pubmed: 32241520
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):631-640
pubmed: 32589990
Radiother Oncol. 2020 Jun;147:229-230
pubmed: 32342875
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32423899
ESMO Open. 2020 Jun;5(Suppl 3):
pubmed: 32581069
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618-627
pubmed: 32302681
Radiother Oncol. 2020 Aug;149:73-77
pubmed: 32389752
J Gastrointest Cancer. 2020 Sep;51(3):800-804
pubmed: 32656628
Radiother Oncol. 2020 Oct;151:15-16
pubmed: 32673779
Radiother Oncol. 2020 Sep;150:40-42
pubmed: 32544604
Radiother Oncol. 2020 Jun;147:84-85
pubmed: 32247204
Radiol Med. 2020 May 15;:
pubmed: 32415472
Nat Rev Clin Oncol. 2020 Jun;17(6):332-334
pubmed: 32341524
Radiother Oncol. 2020 May;146:223-229
pubmed: 32342863
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):e160-e161
pubmed: 32354669
Radiat Oncol. 2020 Jul 9;15(1):166
pubmed: 32646454
Radiother Oncol. 2020 Jul;148:194-200
pubmed: 32342878
Br J Cancer. 2020 Sep;123(5):709-713
pubmed: 32641867
Radiother Oncol. 2020 Sep;150:191-194
pubmed: 32621832
J Appl Clin Med Phys. 2020 May;21(5):6-12
pubmed: 32324950
Radiother Oncol. 2020 Aug;149:89-93
pubmed: 32413527
J Glob Health. 2020 Jun;10(1):010367
pubmed: 32566158
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
Lung Cancer. 2020 Aug;146:230-235
pubmed: 32585497
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Clin Oncol (R Coll Radiol). 2020 Aug;32(8):481-489
pubmed: 32405158
Head Neck. 2020 Jul;42(7):1482-1490
pubmed: 32557972
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):398-406
pubmed: 32690870
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32439716